Precocious puberty suppression injection cost in South Korea
Gonadotropin-releasing hormone agonists, commonly called GnRH agonists, are used to suppress abnormally early pubertal progression in children with central precocious puberty. Korean pediatric indications include leuprorelin and triptorelin products administered every four weeks, three months, or six months. The cost is not determined by the sticker price alone: the child’s documented onset date, first treatment date, Tanner stage, bone-age finding, GnRH stimulation result, planned dose dates, and Korean National Health Insurance end age all matter.
What the dedicated Korean calculator does
- Checks the published initial reimbursement conditions from actual calendar dates and recorded test values.
- Counts administrations under four-week, three-month, and six-month schedules.
- Rechecks every planned administration against the girl’s 12th or boy’s 13th birthday.
- Separates estimated covered doses from full-self-pay doses and adds only user-confirmed visit or test out-of-pocket amounts.
- Compares five MFDS-authorized pediatric regimens using the July 1, 2026 HIRA ceiling prices.
This is a South Korea-specific budget and rule-checking guide, not medical advice, a diagnosis, a prescription, a dose selector, or a HIRA coverage decision. The shared English calculator above this guide is a simplified planning scenario. It does not reproduce the dedicated Korean calculator’s date-by-date dose schedule, weight cautions, or eligibility checklist, so use the Korean surface when those details affect the budget.
Korean reimbursement checklist current in 2026
HIRA’s GnRH agonist reimbursement criteria related to Ministry of Health and Welfare Notice No. 2024-100 took effect on January 1, 2025. The rule does not use age alone. It combines pubertal stage, the documented onset date of secondary sexual characteristics, advanced bone age, a GnRH stimulation test, and the age at first treatment.
South Korea central precocious puberty GnRH agonist reimbursement checklist| Check | Girls | Boys | Shared requirement |
|---|
| Secondary-characteristic onset | Before 8th birthday | Before 9th birthday | Tanner stage 2 or higher |
| Bone age | Advanced beyond chronological age | Advanced beyond chronological age | Assessed before initial treatment |
| GnRH stimulation | Peak LH 5 IU/L or higher | Peak LH 5 IU/L or higher | At least 2-fold above baseline LH |
| First treatment | Before 9th birthday | Before 10th birthday | After the required evaluation |
| Covered-treatment end | Through day before 12th birthday | Through day before 13th birthday | Rechecked for each dose date |
Historical onset evidence can matter
HIRA’s question-and-answer material explains that documentation can establish onset before the age cutoff even when the child reaches care later. Enter the date supported by the medical record rather than the first specialist appointment automatically.
A checklist is not a diagnosis
Growth velocity, physical examination, bone age, the assay and sampling protocol, and evaluation for an underlying cause remain clinical matters. A peak LH result or green calculator badge cannot establish central precocious puberty by itself.
The public text describes the stimulated LH value as rising two to three times above baseline. The calculator treats 2-fold as the minimum and does not reject a value merely because it exceeds 3-fold. If baseline LH is zero, the ratio cannot be calculated reliably from the entered numbers, so the ratio check is marked unmet rather than treated as infinite.
July 1, 2026 HIRA ceiling prices used by the calculator
HIRA’s public List of Reimbursed Drugs and Ceiling Prices effective July 1, 2026 supplies the five preset prices below. Each is a public ceiling amount for one vial or prefilled unit. It is not a national all-inclusive visit price and does not include consultation, injection administration, bone-age imaging, hormone tests, or a GnRH stimulation test.
Korean GnRH agonist pediatric product ceiling prices effective July 1, 2026| Product preset | Ingredient | Planning interval | Ceiling price | Product code |
|---|
| Lupron DPS 3.75 mg | Leuprorelin | Every 4 weeks | KRW 105,299 | 696300391 |
| Diphereline PR 3.75 mg | Triptorelin | Every 4 weeks | KRW 102,825 | 681400031 |
| Lupron DPS 11.25 mg | Leuprorelin | Every 3 months | KRW 189,358 | 696300401 |
| Diphereline PR 11.25 mg | Triptorelin | Every 3 months | KRW 314,474 | 681400041 |
| Diphereline SR 22.5 mg | Triptorelin | Every 6 months / 24 weeks | KRW 615,913 | 681400141 |
Weight-based dose does not guarantee a proportionally smaller bill
MFDS product information includes partial-unit pediatric dosing for some products. Diphereline PR 3.75 mg, for example, distinguishes children below 20 kg, from 20 kg to below 30 kg, and at least 30 kg. Lupron DPS 11.25 mg describes a half dose below 20 kg, while Diphereline PR 11.25 mg pediatric use is stated for children over 20 kg. Remaining product may be discarded, and the claim unit may not fall in direct proportion to the administered fraction. The calculator therefore starts with one published unit price per administration and lets the user replace it with the provider-confirmed amount.
A leuprorelin 22.5 mg product was not included merely because its strength resembles a long-acting triptorelin option. The MFDS page checked for that leuprorelin product did not provide the pediatric central-precocious-puberty indication and stated that pediatric safety had not been established. Product presets must follow the exact ingredient, product, and pediatric indication rather than strength alone.
Dose count, coverage split, and patient-cost formulas
1Count administrations
A four-week plan uses ceil(months × 52 ÷ 12 ÷ 4). Three- and six-month products use ceil(months ÷ interval months).
2Build expected dates
The first dose is on the budget start date. Four-week dates advance by 28 days; long-acting dates advance by calendar months.
3Price every dose
A dose before the sex-specific coverage-end birthday uses the simplified age and facility drug copay only when all initial checks are met. Otherwise it uses 100%.
Exact budgeting formulas
covered dose patient drug cost = round(unit price × age/facility drug rate)
uncovered dose patient drug cost = unit price × 100%
total patient cost = sum(patient drug cost by dose) + per-visit confirmed cost × dose count + one-time test cost
average monthly budget = round(total patient cost ÷ planning months)
The four-week formula yields 13 administrations for a 12-month planning window. This transparent convention is used consistently in comparison rows, although real appointment delays or clinical adjustments can change the dates. The detailed Korean schedule shows every expected date so it can be compared with the provider’s actual calendar.
Simplified Korean outpatient drug cost-sharing rates by child age and facility| Age on dose date | Clinic | Hospital | General hospital | Tertiary hospital |
|---|
| Under 1 year | 5% | 10% | 15% | 20% |
| At least 1, under 6 | 21% | 28% | 35% | 42% |
| At least 6 | 30% | 40% | 50% | 60% |
These rates are a drug-component simplification from National Health Insurance Act Article 44 and the Enforcement Decree Article 19 and Annex 2, current in 2026. They are not a flat percentage of the full outpatient bill. Tertiary-hospital consultation treatment, item-specific rules, dispensing, and injection fees can behave differently, which is why the calculator accepts a confirmed per-visit patient amount instead of inventing one.
Worked examples with the pure calculation rules
Example 1: 24 months on a three-month product
- Girl born January 15, 2017; documented onset July 15, 2024; first injection July 15, 2025.
- Tanner 2, advanced bone age, baseline LH 2, peak LH 5, and all date checks met.
- Lupron DPS 11.25 mg at KRW 189,358, clinic, 24 months, with no extra entered costs.
Eight administrations occur before the 12th birthday. The list drug cost is KRW 1,514,864. Rounding the 30% patient amount for each administration gives KRW 454,456, with an estimated NHI share of KRW 1,060,408 and an average patient drug budget of KRW 18,936 per month.
Example 2: crossing the female end age
- Girl born January 15, 2014 with qualifying onset and first-treatment records.
- Lupron DPS 3.75 mg at KRW 105,299, every four weeks from December 1, 2025 for three months.
- Expected dates: December 1, December 29, January 26, and February 23.
Coverage ends from January 15, 2026. The first two doses use the 30% clinic rate and the last two use 100%. The list drug cost is KRW 421,196, patient drug cost is KRW 273,778, and estimated NHI share is KRW 147,418. Multiplying the full period by 30% would materially understate the cash risk.
How to use the result responsibly
- Choose the exact product, not just the ingredient. Product strength, pediatric indication, interval, and weight wording must match the prescription.
- Enter documented calendar dates. Birth, onset, first treatment, and the next planned dose answer different rule questions.
- Copy Tanner, bone-age, and LH information from the record. Do not fill a threshold merely because it would produce a covered estimate.
- Replace the public price when the provider gives a claim-specific amount. Partial dosing and discarded remainder do not prove that the billed unit is fractional.
- Add only confirmed patient-paid visit and test amounts. The calculator deliberately avoids a fictional national average for the GnRH test or injection fee.
- Take unmet checks and boundary dates to the treating team. The provider must confirm clinical need, dose, reimbursement, claim units, and the real appointment schedule.
Interpretation limits and practical scenarios
Before treatment starts
Use the tool to organize missing evidence, not to self-diagnose. A qualifying-looking checklist still requires clinical evaluation, cause assessment, and an individualized decision on whether treatment is appropriate.
During continuing treatment
Keep the historic first-injection date and move the planning start to the next expected administration. This separates remaining covered and post-cutoff doses when a birthday approaches.
Comparing longer-acting products
The comparison is financial and scheduling only. Convenience, pain, suppression, availability, weight restrictions, and product selection remain clinical and supply decisions.
When a check is unmet
The calculator prices all doses at 100% as a conservative scenario. Historical onset documentation or clinician interpretation may still affect the real HIRA decision, so review the stated unmet reason.
When growth hormone is discussed
GnRH suppression and growth hormone are different therapies. HIRA notes that growth hormone added only because growth velocity fell during GnRH treatment is full self-pay unless true growth hormone deficiency independently meets coverage.
When the hospital quote is higher
The model starts with drug ceiling cost. Consultation, imaging, stimulation testing, injection administration, additional laboratory work, and non-covered items can explain a larger itemized patient quote.
Treatment purpose, follow-up, and safety
The KDCA health portal, updated July 23, 2026, does not describe GnRH agonist treatment as a general height-enhancement injection for a child with normally timed puberty. Treatment addresses abnormally early pubertal progression, and the decision considers progression, bone age, growth, predicted adult height, psychosocial context, and cause. Puberty can resume after treatment stops.
Follow-up discussion
- Height, weight, and growth velocity, often reviewed every three to six months.
- Pubertal progression and bone-age changes.
- Suppression response and whether scheduled intervals were maintained.
- Headache, flushing, injection-site pain, or other adverse effects.
Prompt medical review
- Breathing difficulty, widespread hives, facial swelling, or another serious allergic reaction.
- Severe pelvic pain or a persistent unexpected symptom.
- Marked injection-site swelling, pain, or infection signs.
- A missed dose or a product and interval different from the prescription.
Frequently asked questions
Does reaching age eight automatically rule out coverage for a girl?
Not necessarily. The onset date, not merely the date of the specialist visit, controls that part of the rule. Historical documentation can matter, while Tanner stage, bone age, stimulation results, and first-treatment age must also be reviewed.
Does peak LH 5 IU/L prove central precocious puberty?
No. It is one published reimbursement threshold. The treating clinician interprets the complete examination, growth pattern, bone age, stimulation protocol, and possible underlying causes.
Why does the calculator use 13 doses for 12 months of a four-week product?
It defines 12 months as 52 planning weeks and divides by four. Actual appointments can shift, so compare the generated date list with the provider schedule.
Is a three-month or six-month product always cheaper and better?
No. The table compares public price and frequency, not clinical suitability. Weight wording, approved use, availability, response, and provider billing all matter.
Is an injection on the 12th birthday still covered for a girl?
The calculator treats the 12th birthday as the first non-covered age date for this rule, so the day before is the last potentially covered day. Confirm the real claim with the provider.
Does the tool subtract Korea’s annual out-of-pocket ceiling?
No. The ceiling depends on annual covered statutory copays and household income tier. Non-covered and full-self-pay items are outside it, so one drug stream cannot produce a reliable refund estimate.
Does the estimate subtract private indemnity insurance?
No. Policy generation, benefit status, exclusions, and outpatient limits differ. Use only a payment amount confirmed by the insurer, outside this medical-benefit calculation.
Are puberty suppression and growth hormone the same injection?
No. A GnRH agonist delays pubertal progression. Growth hormone has different indications and reimbursement criteria. Any combination requires separate clinical and coverage review.
Official sources and update triggers
- HIRA GnRH agonist detailed reimbursement criteria, related to MOHW Notice No. 2024-100 and effective January 1, 2025.
- HIRA List of Reimbursed Drugs and Ceiling Prices, public attachment effective July 1, 2026.
- MFDS NEDrug product pages for Lupron DPS 3.75 mg and 11.25 mg and Diphereline PR 3.75 mg, PR 11.25 mg, and SR 22.5 mg, used to confirm pediatric indication, interval, and weight wording.
- KDCA national health information on precocious puberty, updated July 23, 2026.
- National Law Information OPEN API verification of National Health Insurance Act Article 44, Enforcement Decree Article 19 and Annex 2, and the Rule on Standards for National Health Insurance Medical Benefits Articles 5 and 8, all checked as current for the cited 2026 effective dates.
Sources were last cross-checked on July 27, 2026. Recheck the calculator when HIRA changes onset or treatment-age rules, stimulation thresholds, coverage-end ages, product ceiling prices, or claim guidance; when MFDS changes a pediatric indication or schedule; or when the National Health Insurance Enforcement Decree changes outpatient patient-sharing rates.
Recalculate with the record and the next appointment date
Use documented birth, onset, first-treatment, Tanner, bone-age, and LH information, then replace public prices with the provider’s patient-specific quote. Bring the unmet checks, coverage-end date, product weight note, and administration schedule to the pediatric endocrinology visit for confirmation.